Glaukos Corporation Overview
Pro stress-test →Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company commands a leadership position in minimally invasive glaucoma surgery with its flagship micro-bypass stent technologies.
Strategic Profile
Pro stress-test →The company achieved record net sales of $133.5 million in Q3 2025, representing 38% year-over-year growth, demonstrating strong market momentum. Glaukos maintains a strong balance sheet with significant institutional ownership and absence of debt, positioning it for sustained expansion across its glaucoma, corneal disorder, and emerging retinal disease portfolios.
Competitive Landscape
Pro stress-test →Glaukos competes in the ophthalmic medical device sector against larger diversified medical technology companies including Johnson & Johnson (Accera/JWAK platforms), Bausch + Lomb (glaucoma solutions), and Alcon (traditional and MIGS offerings). The company differentiates through specialized focus on minimally invasive glaucoma surgery and novel dropless delivery platforms.
Industry Context
Glaukos Corporation operates in Medical Devices & Ophthalmic Pharmaceuticals.
Key facts
Founded: 1998 · Headquarters: Aliso Viejo, California · Employees: 995 · Revenue: $383.5M · Market cap: $6.6B